Investigation of Anti-Hyperlipidemic and anti-diabetic Activity of Nimbin in Wistar Rat

Main Article Content

Pavan Kumar Padarthi
Bhuvaneshwari Yogesh Rane
Touseef Begum
B. Lavanya
Aanchal Misra
Mohd Ruman Khan
Sonali A. Bhagat
Vijay Dhondiram Wagh


Finding out whether Nimbin anti-hyperlipidemic and Anti-diabetic Activity effects are at work when administered orally in doses of 2 or 4 mg was the driving force for this study. Hyperlipidemia is becoming more common at a frightening pace. Hyperlipidemia is a medical condition that is rapidly becoming more common. At the present rate of rise, one-third of the population will have diabetes by 2050, and hyperlipidemia will impact almost 30 million Americans by the same year. We tested the anti-hyperlipidemic activity using the Dexamethasone and Triton induced hyperlipidemia paradigm. Oral dosage of 4 mg/kg is more efficacious than oral administration of 2 mg/kg in cases of hyperlipidemia. Nimbin shows promising anti-hyperlipidemic benefits when given intramuscularly at doses of 2 or 4 mg/kg, as shown in the trials.

Article Details